Federal Police officers at Rio de Janeiro/Galeão International Airport detained a 20-year-old Brazilian traveller in the early hours of 11 July after X-ray screening revealed 40 ampoules of tirzepatide – the active ingredient in a new generation of injectable weight-loss medications – hidden in his checked baggage. The suspect had started his journey in Foz do Iguaçu, made a domestic connection in Rio and was booked onward to Palmas via São Paulo/Guarulhos. Because tirzepatide is classified by ANVISA as a prescription-only pharmaceutical and is not yet registered for commercial sale in Brazil, importation without agency authorisation constitutes contraband and a crime against public health. The traveller was charged under Articles 273 and 334-A of the Penal Code and could face up to 15 years in prison if convicted. The incident is the latest in a string of seizures of illicit obesity drugs at Brazilian airports this year. In February ANVISA tightened its risk-profiling criteria for parcels arriving from Paraguay and Argentina, flagging weight-loss injectables as a priority target alongside anabolic steroids. Customs brokers warn corporate transferees that couriering personal medicines into Brazil now carries higher enforcement risk and advise obtaining prior import licences. For mobility and travel managers the case underscores the importance of pre-departure medical briefings for assignees. Employees entering Brazil with prescription drugs should carry original prescriptions translated into Portuguese and keep medications in original packaging to avoid detention or confiscation at the border. ANVISA says it is finalising a fast-track compassionate-use authorisation procedure for travellers who rely on medications not yet approved in Brazil, a move that business chambers have welcomed as a step toward more predictable compliance for short-term assignees.
Source: O Dia
